The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

Expanding clinical trial access locally reduces logistical and financial barriers, making participation feasible for underserved populations. Addressing myths about clinical trials helps patients ...

In total, 5,251 discretized criteria were extracted from 216 protocols. The most frequent criterion was previous chemotherapy/biologics (17%). The multilabel SVM demonstrated a pooled accuracy of 75%.

In today’s globalized pharma environment, technical and supply chain challenges in the clinical trial process create ripple effects felt by stakeholders across regions and functions. This has created ...

The research industry’s approach to building clinical trial equity and inclusion has shifted, bringing a renewed focus to these goals. This is great news: Trials that more accurately represent patient ...